NEDD9 Antibody, Biotin conjugated

說(shuō)明書(shū)

中文名稱(chēng)：

NEDD9兔多克隆抗體, Biotin偶聯(lián)
貨號(hào)：

CSB-PA622771LD01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱(chēng)：

Rabbit anti-Homo sapiens (Human) NEDD9 Polyclonal antibody
Uniprot No.：

Q14511
基因名：

NEDD9
別名：

Cas like docking antibody; Cas scaffolding protein family member 2 antibody; CAS-L antibody; CAS2 antibody; CasL antibody; CASL_HUMAN antibody; CASS2 antibody; Crk associated substrate related antibody; Crk associated substrate related protein antibody; CRK-associated substrate-related protein antibody; dJ49G10.2 (Enhancer of Filamentation 1 (HEF1)) antibody; dJ49G10.2 antibody; dJ761I2.1 (enhancer of filamentation (HEF1)) antibody; dJ761I2.1 antibody; Enhancer of filamentation 1 antibody; Enhancer of filamentation 1 p55 antibody; HEF 1 antibody; HEF1 antibody; NEDD-9 antibody; Nedd9 antibody; Neural precursor cell expressed developmentally down-regulated protein 9 antibody; P105 antibody; Renal carcinoma antigen NY-REN-12 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Enhancer of filamentation 1 protein (68-151AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Biotin
克隆類(lèi)型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Docking protein which plays a central coordinating role for tyrosine-kinase-based signaling related to cell adhesion. May function in transmitting growth control signals between focal adhesions at the cell periphery and the mitotic spindle in response to adhesion or growth factor signals initiating cell proliferation. May play an important role in integrin beta-1 or B cell antigen receptor (BCR) mediated signaling in B- and T-cells. Integrin beta-1 stimulation leads to recruitment of various proteins including CRK, NCK and SHPTP2 to the tyrosine phosphorylated form. Required for correct adhesion and migration of T-cells.
基因功能參考文獻(xiàn)：
1. NEDD9, E-cadherin and gamma-catenin proteins have roles in pancreatic ductal adenocarcinoma PMID: 29924959
2. Results reveal the role of a phosphorylation-dependent HEF1-Plk1 complex in HEF1 translocation to FAs to induce cell migration. PMID: 29191835
3. Overexpression of NEDD9 promotes cell invasion and metastasis in hepatocellular carcinoma. Also, NEDD9 may serve as potential therapeutic target for the treatment of hepatocellular carcinoma. PMID: 28578938
4. MiR-125a-5p may serve as a therapeutic agent for lung adenocarcinoma through its major target, NEDD9. PMID: 28714018
5. NEDD9 deregulated Smad7 expression to inhibit Smad signaling and binding to the FAK-Src-Crk complex which is proposed that this is the mechanism by which NEDD9 induced greater sphere formation in cancer stem cells properties. PMID: 27974675
6. HIP2 regulates mitotic spindle alignment. SHIP2 is expressed in G1 phase, whereas Aurora A kinase is enriched in mitosis. SHIP2 binds Aurora A kinase and the scaffolding protein HEF1 and promotes their basolateral localization at the expense of their luminal expression connected with cilia resorption. PMID: 27926875
7. The protein expression level of NEDD9 is higher in esophageal carcinoma tissues than that in adjacent normal tissues. Knockdown of NEDD9 expression can restrain the proliferation, invasion and migration of EC109 cells. PMID: 27916098
8. NEDD9 was able to partially overcome the inhibitory effects of miR-203 on colorectal cancer cell colony formation and invasion. PMID: 27771718
9. Increased NEDD9 expression is associated with metastatic endometrial and lung cancers. PMID: 26701889
10. NEDD9 has an essential role in development as well as in neoplastic cell proliferation, apoptosis, adhesion, migration and invasion. (Review) PMID: 26324022
11. The presence of the dna fragment in the NSCLC-N6-L16 cell ChIP assays demonstrated a physical link between NEDD9 and p53. PMID: 26011298
12. siRNA suppression of NEDD9 inhibits proliferation and enhances apoptosis in renal cell carcinoma. PMID: 26351211
13. Serum NEDD9 was elevated in gastric cancer patients and had an unfavorable prognostic effect. PMID: 26211595
14. BCAR3 is an essential interactor and mediator of HEF1-induced migration. PMID: 25817040
15. Study uncovers a new role of NEDD9 as a regulator of integrin trafficking through CAV1-dependent endocytosis, and provide new insight into the regulation of migration of breast cancer cells. PMID: 25319010
16. miR145 is inversely correlated with NEDD9 expression in pancreatic cancer tissues and restoration of miR145 in Panc1 cells reduced NEDD9 mRNA and protein expression accompanied by inhibition of cell proliferation, invasion and migration. PMID: 25646678
17. Results establish a novel role for NEDD9 as a key regulator of Arf6-dependent trafficking of MMP14 and its invasive properties, highlighting the basic mechanism utilized by NEDD9 to support breast cancer cell invasion and metastasis. PMID: 25241893
18. discuss emerging evidence supporting involvement of NEDD9 in additional pathological conditions, including stroke and polycystic kidney disease PMID: 25967390
19. our findings suggest that NEDD9 acts as an oncogene and promotes GC metastasis via EMT. PMID: 25577245
20. The expression of Nedd9 was upregulated in gastric cancer, high expression of Nedd9 significantly correlated with cancer progression and poor prognosis in gastric cancer. PMID: 24906654
21. Knockdown of the NEDD9 gene results in suppression of lung adenocarcinoma cell proliferation, migration, invasion and cell growth in vitro and in vivo PMID: 25051398
22. NEDD9 expression in breast cancer cells enhances the expression of chondroitin sulfate glycosaminoglycans, particularly the CS-E subunit that enhances growth. PMID: 25445787
23. NEDD9 binds to and regulates acetylation of CTTN in an Aurora A kinase (AURKA)/HDAC6-dependent manner. PMID: 24574519
24. Colorectal adenocarcinoma patients with a higher NEDD9 expression had a significantly shorter overall survival. PMID: 24966970
25. Data reveal that NEDD9 can regulate 3D migration speed independent of the Rac1 morphology switch. PMID: 24337070
26. NEDD9 may be used as a biomarker in the clinical setting to predict the prognosis of gastric cancer patients. PMID: 24664584
27. Obtained data revealed remarkable increase in the expression levels of GHR and NEDD9 proteins in both epithelial and stromal components of axillary lymph node metastases in comparison with those of non-metastatic tumours. PMID: 24676793
28. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. PMID: 24469954
29. Depletion of NEDD9 impaired invasion of cancer cells through inactivation of membrane-bound matrix metalloproteinase MMP14 by excess TIMP2 on the cell surface. PMID: 24202705
30. NEDD9 promotes migration and invasion in cervical carcinoma cells, probably via a positive feedback loop of tyrosine phosphorylation between NEDD9 and FAK or SRC. PMID: 24058594
31. NEDD9 regulates epithelial-mesenchmal transition and cell invasion in prostate cancer cells induced by TGF-beta. PMID: 24728978
32. Data indicate that NEDD9 knockdown significantly inhibits migration, invasion and metastasis of lung cancer cells in vitro and in vivo. PMID: 24174333
33. NEDD9 overexpression is an independent factor of poor prognosis and may serve as a potential biomarker in epithelial ovarian cancer PMID: 24439227
34. The mean overall survival of NSCLC patients overexpressing NEDD9 (39.10 +/- 6.49 months) was markedly shorter. PMID: 23086683
35. The findings indicate that HEF1 promotes EMT and bone invasion in prostate cancer by directly targeted by miR-145, and miR-145 suppresses EMT and invasion, at least in part, through repressing HEF1. PMID: 23355420
36. NEDD9 is upregulated in lung adenocarcinoma, and overexpression of NEDD9 protein has been strongly correlated with staging and differentiation grade and tumor size in lung adenocarcinoma. PMID: 22447485
37. High NEDD9 expression is associated with pancreatic ductal adenocarcinoma. PMID: 23247867
38. Overexpression of NEDD9 promoted lung metastasis of an lung cancer cell line in transgenic mice. PMID: 23037767
39. Results demonstrate the critical role of miR-145 and NEDD9 in regulating glioblastoma invasion and suggest a potential role of NEDD9 as a biomarker for glioma progression. PMID: 22869051
40. In clinical specimens, elevated expression of NEDD9 was associated with malignant progression and metastasis.CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. PMID: 23074285
41. signalling through increased NEDD9 levels requires integrin beta3 signalling, which leads to elevated phosphorylation of integrin beta3 PMID: 22328516
42. The GG genotype of NEDD9 rs760678 polymorphism would be a protective factor for AD in Caucasians but not in Asians.[meta-analysis] PMID: 22963925
43. Abl family kinases modulate T cell-mediated inflammation and chemokine-induced migration through the adaptor HEF1 and the GTPase Rap1. PMID: 22810897
44. HEF1 may have a role in carcinogenesis of lung cancer; miRNA be a therapeutic target PMID: 22732573
45. Polymorphism, rs760678, within NEDD9 gene is association with the risk of AD and cognitive performance in Chinese older persons PMID: 21399483
46. Data reveal that the tumour suppressor PP2A may act via S369 to regulated NEDD9-mediated cell spreading. PMID: 22061964
47. Cas proteins do not affect E-cadherin transcription, but rather, BCAR1 and NEDD9 signal through SRC to promote E-cadherin removal from the cell membrane and lysosomal degradation. PMID: 21765937
48. Data suggest that HEF1 may represent an attractive candidate for drug targeting in CRC. PMID: 21317929
49. NEDD9 polymorphism has a possible role in changing the genetic susceptibility to late-onset Alzheimer's disease in a Han Chinese population. PMID: 21059344
50. HEF1 is required for VEGF-mediated Head and Neck Squamous Cell Carcinoma cell migration and invasion. PMID: 20498643
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm, cell cortex. Nucleus. Golgi apparatus. Cell projection, lamellipodium. Cytoplasm. Cell junction, focal adhesion. Note=Localizes to both the cell nucleus and the cell periphery and is differently localized in fibroblasts and epithelial cells. In fibroblasts is predominantly nuclear and in some cells is present in the Golgi apparatus. In epithelial cells localized predominantly in the cell periphery with particular concentration in lamellipodia but is also found in the nucleus. Isoforms p105 and p115 are predominantly cytoplasmic and associate with focal adhesions while p55 associates with mitotic spindle.; [Enhancer of filamentation 1 p55]: Cytoplasm, cytoskeleton, spindle.
蛋白家族：

CAS family
組織特異性：

Widely expressed. Higher levels detected in kidney, lung, and placenta. Also detected in T-cells, B-cells and diverse cell lines. The protein has been detected in lymphocytes, in diverse cell lines, and in lung tissues.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 7733

OMIM: 602265

KEGG: hsa:4739

STRING: 9606.ENSP00000368759

UniGene: Hs.37982

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human